Magnesium Sulfate Anhydrous

Summary

Magnesium Sulfate Anhydrous (CHEMBL2021423) is an approved small-molecule anticonvulsant; indicated across 32 conditions including preeclampsia and thrombotic thrombocytopenic purpura.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 32 conditions
• Clinical trials: 17
• Chemistry: 120.37 Da · MgO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2021423
Name	Magnesium Sulfate Anhydrous
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	24083
ChEBI	CHEBI:32599
Molecular formula	MgO4S
Molecular weight	120.37
InChIKey	CSNNHWWHGAXBCP-UHFFFAOYSA-L

SMILES: [O-]S(=O)(=O)[O-].[Mg+2]

IUPAC name: magnesium sulfate

ChEBI definition: A magnesium salt having sulfate as the counterion.

Pharmacological roles (ChEBI): anticonvulsant, cardiovascular drug, calcium channel blocker, anaesthetic, tocolytic agent, anti-arrhythmia drug, analgesic.

Other ChEBI roles (chemical / environmental): fertilizer.

Also known as: Magnesium sulfate anhydrous, Magnesium sulfate, anhydrous, Magnesium sulphate anhydrous, Magnesium sulphate, Mgso4, MAGNESIUM SULFATE ANHYDROUS

Parent form; salt/anhydrous children: CHEMBL3989857

Patent coverage: 252,447 distinct patent families (611,235 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

26 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
preeclampsia	3	MONDO:0005081	EFO:0000668
thrombotic thrombocytopenic purpura	3	MONDO:0018896	MONDO:0018896
asthma	3	MONDO:0004979	MONDO:0004979
pancreatitis	3	MONDO:0004982	EFO:0000278
chronic obstructive pulmonary disease	3	MONDO:0005002	EFO:0000341
stroke disorder	3	MONDO:0005098	EFO:0000712
placenta praevia	3	MONDO:0005918	EFO:0007442
poisoning	3	MONDO:0029000	EFO:0008546
cerebral palsy	3	MONDO:0006497	EFO:1000632
periventricular leukomalacia	3	MONDO:0015742	EFO:1001101
pulmonary edema	3	MONDO:0006932	EFO:1001134
placental abruption	3	MONDO:0004846	EFO:1001754
pharyngitis	3	MONDO:0002258	MONDO:0002258
sickle cell disease	3	MONDO:0011382	MONDO:0011382
brain injury	3	MONDO:0043510	MONDO:0043510
glioma	3	MONDO:0021042	MONDO:0100342
perinatal asphyxia	2	MONDO:0006663	EFO:1000824
atrial fibrillation	2	MONDO:0004981	EFO:0000275
mesothelioma	2	MONDO:0005065	EFO:0000588
neuralgia	2	MONDO:0021667	EFO:0005762
brain ischemia	2	MONDO:0005299	HP:0002637
bronchiolitis	2	MONDO:0002465	HP:0011950
hypotensive disorder	1	MONDO:0005468	EFO:0005251
head and neck cancer	1	MONDO:0005627	EFO:0006859
cardiac arrest	1	MONDO:0000745	EFO:0009492
persistent fetal circulation syndrome	1	MONDO:0022430	EFO:1001103

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	6
Not specified	5
PHASE2/PHASE3	3
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06720337	PHASE4	NOT_YET_RECRUITING	Comparative Study Between the Analgesic Effect of Dexmedetomidine and Magnesium Sulfate as Adjuvant to Bupivacaine Using Ultrasound-Guided Transversus Abdominis Plane Block in Abdominal Hysterectomy : A Randomized Double-blinded Study
NCT01025245	PHASE4	COMPLETED	Effect of Intraoperative Magnesium on Remifentanil-induced Postoperative Hyperalgesia After Thyroidectomy
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03318471	PHASE4	COMPLETED	Magnesium Sulphate for Attenuation of Hemodynamic Pressor Response After Myfield’s Clamp Application
NCT04632524	PHASE4	COMPLETED	Evaluation of the Role of Low Dose Magnesium Sulfate in Anesthesia for Toxic Goiter Resection
NCT05609955	PHASE4	COMPLETED	Effects Of Additional MgSO4 30 Mg/KgBW Intravenous and Ketorolac
NCT05736744	PHASE2/PHASE3	RECRUITING	Effect of Magnesium Sulphate Pretreatment in Pediatric Abdominal Surgery
NCT06676475	PHASE2/PHASE3	NOT_YET_RECRUITING	Comparison Between Botox and Magnesium Sulfate Effect in Treatment of Myofascial Pain Trigger Points Within the Masseter Muscle
NCT01846156	PHASE3	COMPLETED	New Magnesium Sulphate Protocol for Pre-eclampsia
NCT03008850	PHASE2/PHASE3	COMPLETED	Shivering Prevention During Cesarean Section by Intrathecal Injection of Magnesium Sulfate
NCT04705142	PHASE2	COMPLETED	Beneficial Effect of Intravenous Magnesium Sulphate in Term Neonates With Hypoxic Ischemic Encephalopathy(HIE)
NCT05158647	PHASE2	COMPLETED	Adding Magnesium Sulfate to Bupivacaine for Ilioinguinal and Iliohypogastric Nerve Block
NCT07199595	Not specified	NOT_YET_RECRUITING	Dexmedetomidine Versus Magnesium Sulfate Infusion in Craniotomy
NCT02538718	Not specified	COMPLETED	Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor
NCT03412552	Not specified	COMPLETED	Risk Analysis of Intensive Care Mangement on Maternal and Fetal Outcome of Severe Preeclampsia and Eclampsia
NCT03891498	Not specified	UNKNOWN	The Effect of Loading Dose of Magnesium Sulfate on Uterine, Umbilical, and Fetal Middle Cerebral Arteries Doppler, Biophysical Profile, CTG, Maternal Vital Signs in Women With Severe Preeclampsia
NCT04401852	Not specified	UNKNOWN	Magnesium Sulfate for Fetal Neuroprotection

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).